The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; none of the 114 sources its claims cite is checked for support yet.
Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies
Open accessAbstract
Major depressive disorder is among the most prevalent and disabling conditions in global medicine, yet its biological underpinnings remain incompletely understood, and current pharmacological treatments fail to produce adequate responses in approximately one-third of patients. A rapidly accumulating body of evidence has not simply challenged the long-dominant monoamine deficiency hypothesis but has provided a mechanistic framework that may explain many of the observed monoaminergic alterations in depressive cohorts, including IDO1-driven serotonin depletion, cytokine-mediated AMPA receptor internalization, and HPA-immune feedback dysregulation. Neuroinflammation, particularly glial activation across microglial, astrocytic, and oligodendrocyte lineages, and its downstream consequences for tryptophan metabolism, glutamatergic transmission, synaptic plasticity, and neurotrophic signaling, represents a central pathophysiological mechanism in a substantial subgroup of depressed patients. Peripheral inflammatory markers, including C-reactive protein, interleukin-6, and tumor necrosis factor-alpha, are elevated in a significant proportion of individuals with major depressive disorder, and these elevations predict poor response to conventional antidepressants while identifying patients who may respond preferentially to anti-inflammatory strategies. Post-mortem studies, positron emission tomography imaging of translocator protein density, and transcriptomic analyses of brain tissue have collectively provided consistent, though not yet fully definitive, evidence that microglial activation is a neurobiological feature of depression rather than a consequence of comorbid physical illness. This review synthesizes current mechanistic understanding of the neuroinflammatory hypothesis of depression, examines the evidence base from epidemiological, biomarker, neuroimaging, and interventional studies, including null findings and methodological limitations, evaluates emerging therapeutic strategies targeting the immune-brain interface, and identifies the critical questions that will determine whether immunopsychiatry fulfills its promise as a precision medicine framework for treatment-resistant depression.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes mechanistic, epidemiological, neuroimaging, and trial evidence for the neuroinflammatory hypothesis of depression, arguing that inflammation provides an upstream explanation for many monoaminergic and glutamatergic alterations rather than replacing the monoamine model. It concludes that anti-inflammatory therapies appear effective only in biomarker-enriched subgroups (roughly 25–40% of clinical samples at CRP > 3 mg/L) and that biological subtyping is now the central clinical imperative.
Key findings
- Peripheral inflammatory markers (CRP, IL-6, TNF-α, IL-1β) are consistently elevated in MDD versus controls with small-to-medium effect sizes; prospective cohorts show elevated IL-6 in midlife predicting depression over the following decade (Whitehall II) and elevated CRP prospectively associated with incident depression and antidepressant prescription in a Danish cohort of over 73,000 individuals.
- TSPO-PET and post-mortem studies show regionally elevated glial markers in corticolimbic circuits (prefrontal cortex, anterior cingulate, insula), with binding correlating with symptom severity, but findings are heterogeneous and TSPO is not microglia-specific; single-cell work reports a transcriptional profile of inhibited/immune-suppressed cortical gray matter microglia rather than canonical activation.
- The inflammatory subtype is estimated at 25–40% of clinical samples at CRP thresholds above 3 mg/L, with atypical features (hypersomnia, increased appetite, fatigue, psychomotor slowing) and greater anhedonia than sadness; elevated CRP/IL-6/TNF-α are higher in treatment-resistant than treatment-responsive patients.
- In the infliximab RCT (N = 60), no overall antidepressant benefit was seen, but significant improvement occurred in the subgroup with baseline CRP above 5 mg/L; a four-week minocycline RCT (N = 70, treatment-resistant depression with elevated CRP) showed significant symptom reduction versus placebo with effect size increasing across baseline inflammation tertiles. Trials in unselected populations reported null results.
Methods
- Narrative synthesis (not a formal systematic review) of mechanistic, epidemiological, neuroimaging, and clinical trial evidence, with emphasis on studies published between 2015 and 2025.
- Literature identified via PubMed and Scopus searches using terms including neuroinflammation, depression, microglia, astrocytes, oligodendrocytes, TSPO, kynurenine pathway, IDO1, CRP, IL-6, TNF-alpha, glutamate, BDNF, anti-inflammatory antidepressants, and treatment-resistant depression; reference lists of identified reviews were hand-searched for primary experimental studies.
- Studies selected on mechanistic, biomarker, or clinical relevance to the neuroinflammatory hypothesis; the paper includes a table of key randomized and interventional anti-inflammatory trials organized by therapeutic class, including null results.
Limitations
- Stated by the paper: the approach "does not constitute a formal systematic review," and the synthesis "may not exhaustively capture all available evidence," though negative and null findings are incorporated throughout.
- Stated by the paper: cytokine measurement is subject to pre-analytical variability, protein instability (particularly IL-1β and TNF-α), and platform-dependent assay sensitivity; TSPO-PET results are influenced by the rs6971 polymorphism, reference region choice, kinetic modeling, and medication status, and TSPO reflects mitochondrial/metabolic activation rather than a specific pro-inflammatory program.
- Stated by the paper: the case for CRP as a clinically actionable stratification biomarker "awaits confirmation from prospective, pre-registered, biomarker-stratified trials," the evidence base for CRP predicting antidepressant non-response is "preliminary rather than definitive," and the depression-associated microglial state has not been precisely characterized at the single-cell transcriptomic level in human tissue.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 3 Not valid · 86 Not checked · 36 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Some studies report no significant difference in TSPO binding between depressed patients and controls”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Microglial activation in depressed brain: neuroimaging and neuropathological evidence > TSPO-PET imaging of microglial activation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Depression is not confined to primary psychiatric illness but emerges as a high-prevalence comorbidity across major neurological, infectious, autoimmune, and systemic diseases in which neuroinflammatory mechanisms are operative, underscoring the transdiagnostic relevance of the immunopsychiatric framework.”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Neuroinflammation-associated depression across disease contexts
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“methodological factors, including the rs6971 TSPO polymorphism, choice of reference region, radioligand kinetic modeling approach, and patient medication status, substantially influence binding estimates and limit cross-study comparability.”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Microglial activation in depressed brain: neuroimaging and neuropathological evidence > TSPO-PET imaging of microglial activation
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“healthy volunteers administered bacterial lipopolysaccharide develop transient depressive and anhedonic symptoms in direct proportion to their inflammatory response”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Introduction
What the sources say
- Not checked yetcites [5] Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–38. source
- Not checked yetcites [6] Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Wohleb and colleagues demonstrated that microglial activation in post-mortem depression tissue is accompanied by transcriptional signatures consistent with an inflammatory state, with enrichment for NF-kappaB target genes, complement pathway components, and chemokine receptors [34].”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Microglial activation in depressed brain: neuroimaging and neuropathological evidence > Post-mortem neuropathology
What the sources say
- Not checked yetcites [34] Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 2016;17:497–511. source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
57 more claims
Create a free account to see all 125 claims and to verify the 114 references still open.
- It may state two separate claims as one. 60
- Probably not a substantial claim. 4
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > The inflammatory depression subtype: clinical features and biomarker stratification
“| Anti-inflammatory agent | RCT | TBD | Unselected/minimal enrichment | Depression scale | Null result - no significant antidepressant benefit; negative trial underscoring need for biomarker selection [63, 64] |”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > References
“64. Husain MI, Chaudhry IB, Khoso AB, Husain MO, Hodsoll J, Ansari MA, et al. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. Lancet Psychiatry. 2020;7:515–27. 32445690”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > The inflammatory depression subtype: clinical features and biomarker stratification
“| Minocycline | RCT | 70 | Elevated CRP | QIDS | Significant symptom reduction vs. placebo; effect size increased with baseline CRP tertile [66] |”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > References
“66. Huang H, Zou Z, Chen B. Efficacy of minocycline in depression: a systematic review and meta-analysis. Clin Neuropharmacol. 2025;48:1–6. 39591510”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Therapeutic strategies targeting neuroinflammation in depression (Table 1) > Anti-cytokine and anti-TNF therapies
“Preliminary data in treatment-resistant depression with elevated inflammatory markers suggest antidepressant signals in biomarker-enriched populations, with effects most pronounced on anhedonia and fatigue [32].”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > References
“32. Nettis MA, Lombardo G, Hastings C, Zajkowska Z, Mariani N, Nikkheslat N, et al. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. Neuropsychopharmacology. 2021;46:939–48. PMC8096832 33504955”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > Therapeutic strategies targeting neuroinflammation in depression (Table 1) > Minocycline and microglial-targeted strategies
“Nettis and colleagues conducted a four-week randomized controlled trial of minocycline added to ongoing antidepressant treatment in 70 patients with treatment-resistant depression and elevated CRP, finding significant reductions in depressive symptoms compared to placebo, with effect size increasing across tertiles of baseline inflammation [65].”
§ Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies > References
“65. Liu YD, Chang YH, Xie XT, Wang XY, Ma HY, Liu MC, et al. PET imaging unveils neuroinflammatory mechanisms in psychiatric disorders: from microglial activation to therapeutic innovation. Mol Neurobiol. 2025;62:15318–35. PMC12559163 40610825”
Citations
Cites
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
The blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172
Research works printed but not linked: 1
- Sutantio EH, Octaviani ID Neuroinflammation in the pathogenesis of psychiatric disorder. Bulletin of Counseling and Psychotherapy 2025;7. https://doi.org/10.51214/bocp.v7i2.1341. · doi:10.51214/bocp.v7i2.1341
Cited by
Still being checked.
Metadata
- Authors
- Santerre, M., Shcherbik, N., & Sawaya, B. E.
- Affiliations
- Temple University (US)
- Rowan University (US)
- Corresponding author
- Sawaya, Bassel E.
- Venue
- Translational Psychiatry
- Published
- 2026-07-03
- Volume
- 16
- Issue
- 1
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC13616901
- OpenAlex
- W7167285818
- Cited by
- 0
- References
- 68
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor, 87 d)
- Locations
- Translational Psychiatry (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute on Aging (AG054411)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- neuroinflammation, major depressive disorder, microglial activation, astrocytes, oligodendrocytes, tryptophan metabolism, IDO1, serotonin depletion, AMPA receptor internalization, HPA axis dysregulation, C-reactive protein, interleukin-6, TNF-α, antidepressant response, treatment-resistant depression, immunopsychiatry, precision medicine, translocator protein (TSPO), neuroimaging, postmortem brain, transcriptomics, synaptic plasticity, neurotrophic signaling
- MeSH terms
- Neuroinflammatory Diseases, Animals, Antidepressive Agents, Brain, Major Depressive Disorder, Humans, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies. https://app.cochat.ai/papers/10.1038/s41398-026-04255-4
- The paper
- Santerre, M., Shcherbik, N., & Sawaya, B. E. (2026). Neuroinflammation and depression: immune-brain interface mechanisms, biomarker stratification, and therapeutic strategies. Translational Psychiatry. https://doi.org/10.1038/s41398-026-04255-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
